参考文献/References:
[1] 彭君,秦鹏,邢天柱,等.血液透析联合血液透析滤过治疗对糖尿病肾病患者心脏结构及功能的影响[J].中国老年学杂志,2019,39(22):5427-5429.
[2] AKIZAWA T,YAMAGUCHI Y,MAJIKAWA Y,et al.Factors affecting the doses of roxadustat versus darbepoetin alfa for anemia therapy in hemodialysis invalid[J].Ther Apher Dial,2020,6(5):457-459
[3] GROENENDAAL-VAN DE MEENT D,KERBUSCH V,KASPERA R,et al.Effect of kidney function and dialysis on the pharmacokinetics and pharmacodynamics of roxadustat,an oral hypoxia-inducible factor prolyl hydroxylase inhibitor[J].Eur J Drug Metab Pharmacokinet,2021,46(1):141-153.
[4] REKI C' D,KERBUSCH-HERBEN V,N AG ARD M,et al.Pharmacokinetics of roxadustat:a population analysis of 2 855 dialysis- and non-dialysis-dependent patients with chronic kidney disease[J].Clin Pharmacokinet,2021,60(5):759-773.
[5] 董建华,范文静,吴边,等.罗沙司他治疗血液透析患者红细胞生成素低反应性贫血的疗效观察[J].肾脏病与透析肾移植杂志,2021,30(3):211-216
[6] 王霜,张益,应士鑫.富马酸亚铁多库酯钠胶囊和多糖铁复合物胶囊对终末期肾病肾性贫血患者氧化应激的影响比较[J].临床和实验医学杂志,2021,20(4):371-375
[7] QIE S,JIAO N,DUAN K,et al.The efficacy and safety of roxadustat treatment for anemia in patients with kidney disease:a meta-analysis and systematic review[J].Int Urol Nephrol,2021,53(5):985-997
[8] 赵娜,郭一丹,赵春霞,等.重组人促红素联合左卡尼汀对老年血液透析患者肾性贫血治疗效果及氧化应激的影响[J].临床误诊误治,2021,34(4):33-38
[9] 郑可,李雪梅.慢性肾脏病贫血与心血管疾病[J].中国实用内科杂志,2020,40(11):903-907.
[10] 吴海婷,李航.铁剂在肾性贫血治疗中的临床应用[J].临床药物治疗杂志,2021,19(8):13-17.
[11] 程红娟,魏芝薇,史慧,等.罗沙司他治疗维持性血液透析患者难治性肾性贫血的疗效观察[J].实用临床医药杂志,2021,25(14):75-77
[12] 窦海川,郭宏艳,陈燕,等.促红细胞生成素不同给药方式对尿毒症血液透析合并贫血患者炎症及营养状态的影响[J].中国老年学杂志,2019,39(11):2707-2708.
[13] 丁英,叶君,符晓腾,等.不同补铁方法对血透患者贫血及微炎症的影响[J].中国实用内科杂志,2014,34(S2):42-44.
[14] 余群青.罗沙司他在慢性肾脏病患者肾性贫血治疗中的效果评价[J].中外医学研究,2021,19(19):61-64.
[15] 王培培,吴涛.口服罗沙司他对慢性肾脏病并肾性贫血的治疗效果观察[J].山东医药,2020,60(33):73-75.
[16] 徐伟玲.重组人促红素联合蔗糖铁治疗尿毒症贫血患者的疗效及对氧化应激反应的影响[J].透析与人工器官,2021,32(2):23-24.
[17] 别昕,张益民,马祖,等.绿茶提取物抗氧化应激治疗对血液透析患者肾性贫血的影响[J].中国中西医结合肾病杂志,2021,21(7):585-588
[18] BARGNOUX A S,CRISTOL J P,JAUSSENT I,et al.Vitamin E-coated polysulfone membrane improved red blood cell antioxidant status in hemodialysis patients[J].J Nephrol,2013,26 (3):556-563.
[19] 王睿,胡洪涛,胡双,等.罗沙司他治疗慢性肾脏病贫血患者的meta 分析[J].临床肾脏病杂志,2019,19(12):871-876.
[20] YAN Z,XU G.A novel choice to correct inflammation-induced anemia in CKD:oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat[J].Front Med(Lansanne),2020,7:393.
[21] 李艳.蔗糖铁注射液治疗血液透析患者肾性贫血的临床疗效观察[J].中国现代药物应用,2021,15(13):190-192.
[22] CHEN N,HAO C,PENG X,et al.Roxadustat for anemia in patients with kidney disease not receiving dialysis[J].N Engl J Med,2019,381(11):1001-1010
[23] 方玲,常晓燕,汪燕燕,等.罗沙司他治疗肾脏透析患者贫血有效性和安全性的meta分析[J].中国医院药学杂志,2020,40(23):2435-2439.
[24] 史亚男,胡志娟,赵鹏,等.低氧诱导因子-脯氨酰羟化酶抑制剂治疗血液透析患者肾性贫血的疗效和安全性分析[J].中国实用内科杂志,2020,40(11):920-925.
相似文献/References:
[1]周长菊,章旭,曹娟,等.维持性血液透析患者采用不同血液净化方式心脏瓣膜钙化高危因素分析[J].新乡医学院学报,2012,29(04):000.
[2]任 伟,王玉梅,陈永健.老年糖尿病肾病患者血液透析相关肺炎危险因素分析[J].新乡医学院学报,2021,38(1):076.[doi:10.7683/xxyxyxb.2021.01.017]
REN Wei,WANG Yumei,CHEN Yongjian.Analysis of the risk factors of hemodialysis associated pneumonia in elderly patients with diabetic nephropathy[J].Journal of Xinxiang Medical University,2021,38(9):076.[doi:10.7683/xxyxyxb.2021.01.017]
[3]周莉莉,刘 佳,张晓艳.罗沙司他治疗肾性贫血的作用机制及临床研究进展[J].新乡医学院学报,2021,38(5):488.[doi:10.7683/xxyxyxb.2021.05.020]
[4]袁小强,张献朝,赵丽萍.西那卡塞和骨化三醇联合治疗糖尿病肾病血液透析患者继发性甲状旁腺功能亢进症疗效观察[J].新乡医学院学报,2022,39(2):131.[doi:10.7683/xxyxyxb.2022.02.006]
YUAN Xiaoqiang,ZHANG Xianchao,ZHAO Liping.Effect of cinacalcet and calcitriol in the treatment of secondary hyperparathyroidism in diabetic nephropathy patients undergoing hemodialysis[J].Journal of Xinxiang Medical University,2022,39(9):131.[doi:10.7683/xxyxyxb.2022.02.006]
[5]鲁 冰,任东升,陶雅非,等.维持性血液透析与持续不卧床腹膜透析对终末期肾病患者钙磷代谢及氧化应激的影响比较[J].新乡医学院学报,2022,39(9):833.[doi:10.7683/xxyxyxb.2022.09.007]
LU Bing,REN Dongsheng,TAO Yafei,et al.Comparison of the effect of maintenance hemodialysis and continuous ambulatory peritoneal dialysis on calcium and phosphorus metabolism and oxidative stress in patients with end-stage renal disease[J].Journal of Xinxiang Medical University,2022,39(9):833.[doi:10.7683/xxyxyxb.2022.09.007]
[6]王岩,张爱霞,王紫晖,等.碱性成纤维细胞生长因子、血清和糖皮质激素诱导的蛋白激酶3表达与血液透析患者动静脉内瘘失功的关系[J].新乡医学院学报,2023,40(9):851.[doi:10.7683/xxyxyxb.2023.09.009]
WANG Yan,ZHANG Aixia,WANG Zihui,et al.Relationship between the expression of basic fibroblast growth factor,serum and glucocorticoid-induced protein kinase 3 and the dysfunction of arteriovenous fistula in patients undergoing hemodialysis[J].Journal of Xinxiang Medical University,2023,40(9):851.[doi:10.7683/xxyxyxb.2023.09.009]